Style | Citing Format |
---|---|
MLA | Rahmani E, et al.. "Preparation of a Ph-Responsive Chitosan-Montmorillonite-Nitrogen-Doped Carbon Quantum Dots Nanocarrier for Attenuating Doxorubicin Limitations in Cancer Therapy." Engineering in Life Sciences, vol. 22, no. 10, 2022, pp. 634-649. |
APA | Rahmani E, Pourmadadi M, Ghorbanian SA, Yazdian F, Rashedi H, Navaee M (2022). Preparation of a Ph-Responsive Chitosan-Montmorillonite-Nitrogen-Doped Carbon Quantum Dots Nanocarrier for Attenuating Doxorubicin Limitations in Cancer Therapy. Engineering in Life Sciences, 22(10), 634-649. |
Chicago | Rahmani E, Pourmadadi M, Ghorbanian SA, Yazdian F, Rashedi H, Navaee M. "Preparation of a Ph-Responsive Chitosan-Montmorillonite-Nitrogen-Doped Carbon Quantum Dots Nanocarrier for Attenuating Doxorubicin Limitations in Cancer Therapy." Engineering in Life Sciences 22, no. 10 (2022): 634-649. |
Harvard | Rahmani E et al. (2022) 'Preparation of a Ph-Responsive Chitosan-Montmorillonite-Nitrogen-Doped Carbon Quantum Dots Nanocarrier for Attenuating Doxorubicin Limitations in Cancer Therapy', Engineering in Life Sciences, 22(10), pp. 634-649. |
Vancouver | Rahmani E, Pourmadadi M, Ghorbanian SA, Yazdian F, Rashedi H, Navaee M. Preparation of a Ph-Responsive Chitosan-Montmorillonite-Nitrogen-Doped Carbon Quantum Dots Nanocarrier for Attenuating Doxorubicin Limitations in Cancer Therapy. Engineering in Life Sciences. 2022;22(10):634-649. |
BibTex | @article{ author = {Rahmani E and Pourmadadi M and Ghorbanian SA and Yazdian F and Rashedi H and Navaee M}, title = {Preparation of a Ph-Responsive Chitosan-Montmorillonite-Nitrogen-Doped Carbon Quantum Dots Nanocarrier for Attenuating Doxorubicin Limitations in Cancer Therapy}, journal = {Engineering in Life Sciences}, volume = {22}, number = {10}, pages = {634-649}, year = {2022} } |
RIS | TY - JOUR AU - Rahmani E AU - Pourmadadi M AU - Ghorbanian SA AU - Yazdian F AU - Rashedi H AU - Navaee M TI - Preparation of a Ph-Responsive Chitosan-Montmorillonite-Nitrogen-Doped Carbon Quantum Dots Nanocarrier for Attenuating Doxorubicin Limitations in Cancer Therapy JO - Engineering in Life Sciences VL - 22 IS - 10 SP - 634 EP - 649 PY - 2022 ER - |